secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001104659-23-058762
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q1 net loss $31.3M; cash $334.8M; CNTY-101 data expected by year end
--------------------------------------------------------------------------------

- Q1 net loss $31.3M vs $37.5M prior year; R&D expenses $24.9M, G&A $8.9M.
- Cash, equivalents, investments $334.8M as of March 31, 2023; cash runway into 2026.
- CNTY-101 Phase 1 ELiPSE-1 trial ongoing; initial data from Schedule A expected by year end 2023.
- FY2023 GAAP operating expense guidance $135-145M; non-cash stock comp $12-17M.
- Leadership: Greg Russotti interim CEO (since March), Michael Diem CFO, Hy Levitsky President of R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923058762/0001104659-23-058762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923058762/tm2315313d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-058762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer